Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Rix

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Cancer Research|August 1, 2019
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung CancerMengyu Xie, Hong Zheng, Ranjna Madan-Lala, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2013
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cellsJae-Young Kim, Eric A Welsh, Umut Oguz, et al.
Molecular Oncology|November 6, 2025
Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsJuhyeon Son, Lily L Remsing Rix, Bin Fang, et al.
Cell Chemical Biology|November 22, 2016
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsClaire E Knezevic, Gabriela Wright, Lily L Remsing Rix, et al.
Methods (San Diego, Calif.)|March 19, 2015
Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptidesBin Fang, Melissa A Hoffman, Abu-Sayeef Mirza, et al.
Nature Chemical Biology|October 2, 2012
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CMLGeorg E Winter, Uwe Rix, Scott M Carlson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal MelanomaFernanda Faião-Flores, Michael F Emmons, Michael A Durante, et al.
Molecular Cancer Therapeutics|May 20, 2016
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung CancerAnkita Jhuraney, Nicholas T Woods, Gabriela Wright, et al.
Cell Chemical Biology|July 2, 2019
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual TargetsNatalia J Sumi, Claudia Ctortecka, Qianqian Hu, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signalingQianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Cancer Research|August 1, 2019
MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung CancerMengyu Xie, Hong Zheng, Ranjna Madan-Lala, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2013
Dissection of TBK1 signaling via phosphoproteomics in lung cancer cellsJae-Young Kim, Eric A Welsh, Umut Oguz, et al.
Molecular Oncology|November 6, 2025
Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsJuhyeon Son, Lily L Remsing Rix, Bin Fang, et al.
Cell Chemical Biology|November 22, 2016
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsClaire E Knezevic, Gabriela Wright, Lily L Remsing Rix, et al.
Methods (San Diego, Calif.)|March 19, 2015
Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptidesBin Fang, Melissa A Hoffman, Abu-Sayeef Mirza, et al.
Nature Chemical Biology|October 2, 2012
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CMLGeorg E Winter, Uwe Rix, Scott M Carlson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal MelanomaFernanda Faião-Flores, Michael F Emmons, Michael A Durante, et al.
Molecular Cancer Therapeutics|May 20, 2016
PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung CancerAnkita Jhuraney, Nicholas T Woods, Gabriela Wright, et al.
Cell Chemical Biology|July 2, 2019
Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual TargetsNatalia J Sumi, Claudia Ctortecka, Qianqian Hu, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2024
Cancer-associated fibroblasts confer ALK inhibitor resistance in <i>EML4-ALK</i> -driven lung cancer via concurrent integrin and MET signalingQianqian Hu, Lily L Remsing Rix, Bina Desai, et al.
Pageof 9